いまさら訊けない！　透析患者検査値のみかた、考えかた　Ver.2

出版社： 中外医学社
著者：
発行日： 2018-06-15
分野： 臨床医学：内科  >  腎臓
ISBN： 9784498224117
電子書籍版： 2018-06-15 （2版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,740 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,740 円(税込)

購入する

商品紹介

透析患者の血液検査について，その臨床的な意義や診療での注意点などが一目で理解できると好評を博したハンドブックの最新版．初版刊行から約4年，新たなガイドラインも登場し，複数の検査項目が新規保険収載された．これらの大きな変化を受けて全面的に改訂を加える．シスタチンC・ペントシジン・抗MAC抗体など新規項目も多数追加．

目次

  • I　総論
    　1．透析患者の検査は特殊である

    II　定期的に行われる検査
    　2．白血球数/分画
    　3．ヘモグロビン/MCV/MCHC/網状赤血球
    　4．血小板
    　5．ナトリウム/クロール〈小松康宏〉
    　6．カリウム
    　7．pH/重炭酸イオン
    　8．クレアチニン
    　9．血清尿素窒素（BUN）
    　10．尿酸
    　11．リン/カルシウム
    　　Column　線維芽細胞増殖因子（fibroblast growth factor：FGF23）と心血管合併症
    　12．マグネシウム
    　13．GOT（AST）/GPT（ALT）/γ-GTP
    　14．アルカリホスファターゼ
    　15．アルブミン
    　16．コレステロール
    　17．中性脂肪（トリグリセリドtriglyceride：TG）
    　18．C反応性蛋白（CRP）
    　19．鉄/フェリチン
    　　Column　ヘプシジン-25
    　20．副甲状腺ホルモン
    　21．β2-ミクログロブリン
    　22．血糖/ヘモグロビンA1c/グリコアルブミン
    　　Column　血液透析と糖尿病
    　　Column　透析患者の血糖コントロール
    　23．B型肝炎ウイルス（HBV）
    　24．C型肝炎ウイルス（HCV）
    　25．透析効率の指標（Kt/V, URR, nPCR）

    III　病態に応じて行われる検査
    　26．アミラーゼ
    　27．トロポニンT/I，CK
    　28．凝固検査
    　29．体液量マーカー（hANP, BNP, NTpro-BNP）
    　30．シスタチンC
    　31．ペントシジン
    　32．甲状腺ホルモン
    　33．レニン/アルドステロン
    　34．コルチゾール/ACTH
    　35．ビタミンD
    　36．プロカルシトニン/プレセプシン
    　37．インターフェロンγ遊離試験（IGRA）/T-SPOT
    　38．抗MAC抗体（キャピリアMAC抗体）
    　39．深在性真菌症マーカー
    　40．腫瘍マーカー
    　41．自己抗体
    　　Column　透析導入後にSLEやANCA関連血管炎は再燃することはあるの？
    　42．アルブミン以外の生化学的栄養指標（RTP）
    　　Column　理想的な生化学的栄養指標
    　43．微量元素
    　　Column　微量元素とは
    　44．カルニチン
    　45．脂肪酸4分画
    　46．薬物血中濃度

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[I] 総論

P.7 掲載の参考文献
1) Wong G, Li MW, Howard K, et al. Health benefits and costs of screening for cololectal cancer in people on dialysis or who have received a kidney transplant. Nephrol Dial Transplant. 2013 ; 28 : 917-26.
PubMed
2) Minutolo R, Bellizzi V, Cioffi M, et al. Postdialysis rebound of serum phosphrous : pathogenetic and clinical insights. J Am Soc Nephrol. 2002 ; 13 : 1046-54.
 
3) 日本透析医学会. 血液透析患者の糖尿病治療ガイド 2012. 透析会誌. 2013 ; 46 : 311-57.
 
4) Nakatani T, Naganuma T, Masuda C, et al. The prognostic role of atrial natriuretic peptides in hemodialysis patients. Blood Purif. 2003 ; 21 : 395-400.
PubMed
5) 日本透析医学会. 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌. 2011 ; 44 : 337-425.
 

[II] 定期的に行われる検査

P.13 掲載の参考文献
1) 北島信治, 和田隆志. 白血球. In : 秋澤忠男, 他編. 透析患者の検査値の読み方. 日本メディカルセンター. 2013. p.66-7.
 
2) Brown DW, Ford ES, Giles WH, et al. Associations between white blood cell count and risk for cerebrovascular disease mortality : NHANES II Mortality Study, 1976-1992. Ann Epidemiol. 2004 ; 14 : 425-30.
PubMed
3) Tamakoshi K, Toyoshima H, Yatsuya H, et al. White blood cell count and risk of all-cause and cardiovascular mortality in nationwide sample of Japanese--results from the NIPPON DATA90. Circ J. 2007 ; 71 : 479-85.
PubMed
4) 日本透析医学会統計調査委員会. 我が国の慢性透析療法の現況. 2000年12月31日現在.
 
5) Agarwal R, Light RP. Patterns and prognostic value of total and differential leukocyte count in chronic kidney disease. Clin J Am Soc Nephrol. 2011 ; 6 : 1393-9.
PubMed
6) Pifer TB, McCullough KP, Port FK, et al. Mortality risk in hemodialysis patients and changes in nutritional indicators : DOPPS. Kidney Int. 2002 ; 62 : 2238-45.
PubMed
7) Abe T, Kato S, Tsuruta Y, et al. Neutrophil/lymphocyte ratio as a predictor of cardiovascular events in incident dialysis patients : a Japanese prospective cohort study. Clin Exp Nephrol. 2015 ; 19 : 718-24.
 
8) Kaplow LS, Goffinet JA. Profound neutropenia during the early phase of hemodialysis. JAMA. 1968 ; 203 : 133-5.
 
P.21 掲載の参考文献
1) 日本透析医学会. 2015年版慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌. 2016 ; 49 : 89-158.
 
2) Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. Suppl. 2012 ; 2 : 279-335.
 
3) 日本透析医学会. 2008年版慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌. 2008 ; 41 : 661-716.
 
4) Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005 ; 68 : 1337-43.
PubMed
5) Ebben J, Gilbertson DT, Foley RN, et al. Hemoglobin level variability : Associations with comorbidity, intercurrent events, and hospitalization. Clin J Am Soc Nephrol. 2006 : 1205-10.
PubMed
6) Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998 ; 339 : 584-90.
PubMed
P.26 掲載の参考文献
1) Ando M, Iwamoto Y, Suda A, et al. New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels. Blood. 2001 ; 97 : 915-21.
PubMed
2) Linthorst GE, Folman CC, van Olden RW, et al. Plasma thrombopoietin levels in patients with chronic renal failure. Hematol J. 2002 ; 3 : 38-42.
PubMed
3) Daugirdas JT, Bernardo AA. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int. 2012 ; 82 : 147-57.
PubMed
4) Kim S, Molnar MZ, Fonarow GC, et al. Mean platelet volume and mortality risk in a national incident hemodialysis cohort. Int J Cardiol. 2016 ; 220 : 862-70.
 
5) Shin DH, Rhee SY, Jeon HJ, et al. An increase in mean platelet volume/platelet count ratio is associated with vascular access failure in hemodialysis patients. PLoS One. 2017 ; 12 : e0170357.
PubMed
6) Taymez DG, Ucar E, Turkmen K, et al. The predictive value of platelet/lymphocyte ratio in hemodialysis patients with erythropoietin resistance. Ther Apher Dial. 2016 ; 20 : 118-21.
PubMed
7) Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions : Sepsis, hit, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2003 : 497-519.
PubMed
8) Lee GM, Arepally GM. Heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2013 ; 2013 : 668-74.
PubMed
9) Syed S, Reilly RF. Heparin-induced thrombocytopenia : A renal perspective. Nat Rev Nephrol. 2009 ; 5 : 501-11.
PubMed
10) Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012 ; 119 : 2209-18.
 
11) 松尾武文. ヘパリン起因性血小板減少症 (Heparin-induced thrombocytopenia : HIT) の診断. 日本血栓止血学会誌. 2008 ; 19 : 191-4.
 
12) Kiaii M, Djurdjev O, Farah M, et al. Use of electron-beam sterilized hemodialysis membranes and risk of thrombocytopenia. JAMA. 2011 ; 306 : 1679-87.
PubMed
13) 日本透析医学会統計調査委員会. わが国の慢性透析の現状. 2000年12月31日現在.
 
P.33 掲載の参考文献
1) 寺澤文子. 電解質・浸透圧測定. 臨床検査法提要. 改訂32版. 東京 : 金原出版 ; 2005. p.660-7.
 
2) Edelman IS, Leibman J, O'meara MP, et al. Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest. 1958 ; 37 : 1236-56.
PubMed
3) Chawla A, Sterns RH, Nigwekar SU, et al. Mortality and serum sodium : do patients die from or with hyponatremia? Clin J Am Soc Nephrol. 2011 ; 6 : 960-5.
PubMed
4) Iseki K, Uehara H, Nishime K, et al. Impact of the initial levels of laboratory variables on survival in chronic dialysis patients. Am J Kidney Dis. 1996 ; 28 : 541-8.
PubMed
5) Mandai S, Kuwahara M, Kasagi Y, et al. Lower serum sodium level predicts higher risk of infection-related hospitalization in maintenance hemodialysis patients : an observational cohort study. BMC Nephrol. 2013 ; 14 : 276.
PubMed
6) Lambie SH, Taal MW, Fluck RJ, et al. Online conductivity monitoring : validation and usefulness in a clinical trial of reduced dialysate conductivity. ASAIO J. 2005 ; 51 : 70-6.
 
7) Lee SW. Sodium balance in maintenance hemodialysis. Electrolyte Blood Press. 2012 ; 10 : 1-6.
PubMed
8) Munoz Mendoza L, Sun S, Chertow GM, et al. Dialysate sodium and sodium gradient in maintenance hemodialysis. Nephrol Dial Transplant. 2011 ; 26 : 1281-7.
 
9) Flanigan MJ. Sodium flux and dialysate sodium in hemodialysis. Semin Dial. 1998 ; 11 : 298-304.
 
10) Yunos NM, Bellomo R, Story D, et al. Bench to bedside review : Chloride in critical illness. Critical Care. 2010 ; 14 : 226.
PubMed
11) Berend K, van Hulsteijin LH, Gans ROB. Chloride : The queen of electrolyte? Eur J Intern Med. 2012 ; 23 : 203-11.
 
12) 野上清信. 日常検査における異常値への対応Na, K, Cl. 検査と技術. 1993 ; 21 (増刊) : 46.
 
13) Morimitsu H, Rocktachel J, Bellomo R, et al. Comparison of point-of-care versus central laboratory measurement of electrolyte concentrations on calculations of the anion gap and the strong ion difference. Anesthesiology. 2003 ; 98 : 1077-84.
 
14) 上野芳人, 荻野良郎, 木野内喬. クロール. 日本臨牀. 2004 ; 62 (増刊) : 257-60.
 
P.37 掲載の参考文献
1) Palmer BF, DuBose Jr.T D. Disorders of potassium metabolism. In : Schrier RW. editor. Renal and electrolyte disorders. 7th ed. Philadelphia : Lippincott Williams & Wilkins ; 2010. p.137-65.
 
2) 日本透析医学会統計調査委員会. わが国の慢性透析療法の現況. 2012年12月31日現在.
 
3) Torlen K, Kalantar-Zadeh K, Molnar MZ, et al. Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. Clin J Am Soc Nephrol. 2012 ; 7 : 1272-84.
 
4) Han SW, Won YW, Yi JH, et al. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Nephrol Dial Transplant. 2007 ; 22 : 1150-5.
PubMed
5) CKDでは, 血清カリウム値の異常を補正することが推奨されるか? In : 日本腎臓学会, 編. エビデンスに基づくCKD診療ガイドライン 2013. 東京 : 東京医学社 ; 2013. p.34-5.
 
P.42 掲載の参考文献
1) 菱田明, 編. 体液・電解質異常の臨床. 大阪 : 永井書店 ; 1997.
 
2) Bommer J, Locatelli F, Satayathum S, et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004 ; 44 : 661-71.
PubMed
3) Vashistha T, Kalantar-Zadeh K, Molnar MZ, et al. Dialysis modality and correction of uremic metabolic acidosis : Relationship with all-cause and cause-specific mortality. Clin J Am Soc Nephrol. 2013 ; 8 : 254-64.
PubMed
4) Krieger NS, Kevin K, Fric KK, et al. Mechanism of acid induced bone resorption. Curr Opin Nephrol Hypertens. 2004 ; 13 : 423-36.
 
5) Lefebvre A, de Vernejoul MC, Gueris J, et al. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int. 1989 ; 36 : 1112-8.
PubMed
6) 正井基之, 坂井健彦, 内野順司, 他. カーボスター透析液の調整と慢性維持透析患者の酸塩基平衡. 透析会誌. 2013 ; 46 : 651-9.
 
7) De Santo NG, Frangiosa A, Anastasio P, et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol. 2006 ; 19 (Suppl 9) : S108-14.
 
8) 松下和道, 田端秀日朗, 新田孝作, 他. 塩酸セベラマー内服量が血液透析患者の酸塩基平衡に及ぼす影響-クエン酸透析液でも, 代謝性アシドーシスを悪化させるか? 透析会誌. 2010 ; 43 : 373-9.
 
9) K/DOQI, National Kidney Foundation. Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2000 ; 35 (Suppl 2) : S1-S140.
 
10) Fouque D, Vennegoor M, Ter Wee P, et al. EBPG guideline on nutrition. Nephrol Dial Transplant. 2007 ; 22 (Suppl 2) : ii45-87.
 
P.48 掲載の参考文献
1) 橋本佳明. 血清クレアチニン. In : 高久史麿, 監修. 臨床検査データブック 2013-2014. 東京 : 医学書院 ; 2013. p.123.
 
2) 新田孝作. クレアチニン・eGFR. In : 和田治, 他編. 臨床検査ガイド 2013-2014. 東京 : 文光堂 ; 2013. p.221-4.
 
3) 河合忠. クレアチン, クレアチニン. In : 河合忠, 他編. 異常値の出るメカニズム. 第5版 東京 : 医学書院 ; 2008. p.145-8.
 
4) Imai E, Matsuo S, Makino H, et al. Chronic Kidney Disease Japan Cohort (CKD-JAC) study : design and methods. Hypertens Res. 2008 ; 31 : 1101-7.
PubMed
5) 林松彦. クレアチニン. 日医会誌. 2006 ; 135 : S177.
 
6) 日本透析医学会. 維持血液透析ガイドライン. 血液透析処方. 透析会誌. 2013 ; 46 : 587-632.
 
7) Shinzato T, Nakai S, Miwa M, et al. Method to calculate creatinine generation rate using pre- and postdialysis creatinine concentrations. Artif Organs. 1997 ; 21 : 864-72.
PubMed
8) 日本透析医学会統計調査委員会. 図説わが国の慢性透析療法の現況 2009年12月31日現在. 東京 : 日本透析医学会 ; 2010. p.69.
 
P.54 掲載の参考文献
1) 堀尾勝. 尿素窒素 (BUN), 非蛋白窒素 (NPN). 日本臨牀. 2009 ; 67 (増刊号 8) : 651-3.
 
2) Shinzato T, Nakai S, Fujita Y, et al. Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations. Nephron. 1994 ; 67 : 280-90.
 
3) 維持血液透析ガイドライン : 血液透析処方. 日本透析医学会雑誌. 2013 ; 46 : 587-632.
 
4) Fouque D, Vennegoor M, ter Wee P, et al. EBPG guideline on nutrition. Nephrol Dial Transplant. 2007 ; 22 (Suppl 2) : ii45-87.
 
5) 鈴木一之. 透析医が透析患者になってわかったしっかり透析のヒケツ. 東京 : メディカ出版 ; 2010. p.160-8.
 
6) National Kidney Foundation : DOQI Clinical practice guidelines for hemodialysis adequacy. Am J Kidney Dis. 1997 ; 30 (Suppl 2) : S1-63.
 
7) 櫻林耐. 尿素窒素. In : 秋澤忠男, 監修. 透析患者の検査値の読み方. 改訂第3版. 東京 : 日本メディカルセンター ; 2013. p.85-8.
 
P.58 掲載の参考文献
1) 日本透析医学会透析調査委員会. わが国の慢性透析療法の現況. 2011年12月31日現在.
 
2) Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003 ; 41 : 1183-90.
 
3) Bae E, Cho HJ, Shin N, et al. Lower serum uric acid level predicts mortality in dialysis patients. Medicine. 2016 ; 95 : 24 (e3701).
PubMed
4) Park C, Obi Y, Streja E, et al. Serum uric acid, protein intake and mortality in hemodialysis patients Nephrol Dial Transplant. 2017 ; 32 : 1750-7.
PubMed
5) Latif W, Karaboyas A, Tong L, et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol. 2011 ; 6 : 2470-7.
PubMed
6) 菅野直希, 丸山之雄, 木戸口彗, 他. 日本の維持血液透析患者において血清尿酸値が低いほど全死亡および心血管イベントによる死亡のリスクが増加する. 痛風と核酸代謝. 2016 ; 40 : 101.
 
P.68 掲載の参考文献
1) 日本透析医学会. 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌. 2012 ; 45 : 301-36.
 
2) Yokoyama K, Taniguchi M, Fukagawa M. A Japanese approach for CKD-MBD. Kidney Int. 2013 ; Suppl. 3 : 451-6.
PubMed
3) 山村佐保子, 大城戸一郎, 横山啓太郎. 心血管障害とリン. 代謝. Nephrology Frontier. 2013 ; 12 : 378-82.
Medical*Online
4) Yokoyama K, Katoh N, Kubo H, et al. Clinical significance of the K/DOQI bone guidelines in Japan. Am J Kidney Dis. 2004 ; 44 : 383-4.
 
5) 横山啓太郎. リン代謝の新しい知見/FGF23そしてklotho. 透析医会誌. 2014 ; 29 : 98-105.
 
6) Payne RB, Little AJ, Williams RB, et al. Interpretation of serum calcium levels in patients with abnormal serum proteins. Br Med J. 1973 ; 4 : 643-6.
 
7) Goodman WG, Hladik GA, Turner SA, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002 ; 13 : 1017-24.
PubMed
P.69 掲載の参考文献
1) Isakova T, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011 ; 305 : 2432-9.
PubMed
2) Dominguez JR, et al. Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J Am Soc Nephrol. 2013 ; 24 : 647-54.
PubMed
3) Isakova T, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011 ; 79 : 1370-8.
PubMed
4) Shigematsu T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004 ; 44 : 250-6.
PubMed
5) Scialla JJ, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 2013 ; 83 : 1159-68.
PubMed
6) Mathew S, et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008 ; 19 : 1092-105.
 
7) Raggi P, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002 ; 39 : 695-701.
PubMed
8) Yildiz A, et al. Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients. Nephrol Dial Transplant. 2005 ; 20 : 760-7.
PubMed
9) London GM, et al. Arterial media calcification in end stage renal disease : impact on all-cause and cardiovascular mortality. Nephorol Dial Transplant. 2003 ; 18 : 1731-40.
PubMed
10) Okuno S, et al. Presence of abdominal aortic calcification is significantly associated with all cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2007 ; 49 : 417-25.
PubMed
11) Foley RN, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009 ; 20 : 397-404.
PubMed
12) Adeney KL, et al. Association of serum phosphate with vascular calcification in moderate CKD. J Am Soc Nephrol. 2009 ; 20 : 381-7.
PubMed
13) Faul C, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011 ; 21 : 4393-408.
 
14) Jimbo R, et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int advance online publication, 2 October 2013.
 
P.73 掲載の参考文献
1) Randall RE Jr, Cohen MD, Spray CC Jr, et al. Hypermagnesemia in renal failure : Etiology and toxic manifestation. Ann Intern Med.1964 ; 61 : 73-88.
PubMed
P.78 掲載の参考文献
1) Espinosa M, Martin-Malo A, Alvarez de Lara MA, et al. High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied. Clin Nephrol. 2000 ; 54 : 151-6.
 
2) Ono K, Ono T, Matsumata T. The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase activity in the plasma of hemodialysis patients : the role of vitamin B6 deficiency. Clin Nephrol. 1995 ; 43 : 405-8.
 
3) Crawford DR, Reyna RS, Weiner MW. Effects of in vivo and in vitro dialysis on plasma transaminase activity. Nephron. 1978 ; 22 : 418-22.
PubMed
4) Yasuda K, Okuda K, Endo N, et al. Hypoaminotransferasemia in patients undergoing long-term hemodialysis : clinical and biochemical appraisal. Gastroenterology. 1995 ; 109 : 1295-300.
PubMed
5) Sombolos KI, Fragidis SK, Bamichas GI, et al. Dogma disputed : postdialysis increase of aminotransferase values cannot be attributed to an inhibitor removal by hemodialysis. ASAIO J. 2012 ; 58 : 612-5.
 
6) Sette LH, Almeida Lopes EP. Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis : a comprehensive review. Clinics (Sao Paulo). 2014 ; 69 : 271-8.
PubMed
7) Liberato IR, Lopes EP, Cavalcante MA, et al. Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis. Clinics. 2012 ; 67 : 131-4.
PubMed
8) 小谷一夫, 前川真人, 菅野剛史. 日本臨床化学会 (JSCC) 常用基準法に基づいたaspartate aminotransferase (AST) /alanine aminotransferase (ALT) 比の再設定-Karmen法からJSCC常用基準法への変更に伴う肝疾患評価基準の変化-. 日消誌. 1994 ; 91 : 154-61.
Medical*Online
9) Schiavon LL, Schiavon JL, Filho RJ, et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology. 2007 ; 46 : 307-14.
PubMed
10) Fabrizi F, De Vecchi AF, Qureshi AR, et al. Gamma-glutamyltransferase activity and viral hepatitis in dialysis population. Int J Artif Organs. 2007 ; 30 : 6-15.
PubMed
11) Ruttmann E, Brant LJ, Concin H, et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality : an epidemiological investigation in a cohort of 163, 944 Austrian adults. Circulation. 2005 ; 112 : 2130-7.
 
12) Strasak AM, Goebel G, Concin H, et al. Prospective study of the association of serum gamma-glutamyltransferase with cervical intraepithelial neoplasia III and invasive cervical cancer. Cancer Res. 2010 ; 70 : 3586-93.
PubMed
13) Postorino M, Marino C, Tripepi G, et al. Gammaglutamyltransferase in ESRD as a predictor of all-cause and cardiovascular mortality : another facet of oxidative stress burden. Kidney Int Suppl. 2008 ; (111) : S64-6.
PubMed
14) 日本透析医学会統計調査委員会. わが国の慢性透析療法の現況, 2007年12月31日現在.
 
15) 日本透析医学会統計調査委員会. わが国の慢性透析療法の現況, 2008年12月31日現在.
 
16) 日本透析医学会. 透析患者のC型ウイルス肝炎治療ガイドライン. 透析会誌. 2011 ; 44 : 481-531.
 
17) Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000 ; 11 : 1896-902.
PubMed
P.84 掲載の参考文献
1) Sardiwal S, Magnusson P, Goldsmith DJA, et al. Bone alkaline phosphatase in CKD-mineral bone disorder. Am J Kidney Dis. 2013 ; 62 : 810-22.
PubMed
2) Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016 ; 67 : 559-66.
PubMed
3) Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008 ; 74 : 655-63.
PubMed
4) Drechsler C, Verduijn M, Pilz S, et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol. 2011 ; 6 : 1752-9.
PubMed
5) Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Therapeutic apheresis and dialysis : Official peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. Ther Apher Dial. 2013 ; 17 : 247-88.
PubMed
6) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009 ; 76 : S1-S130.
 
P.88 掲載の参考文献
1) Friedman AN, Fadem SZ. Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol. 2010 ; 21 : 223-30.
PubMed
2) Kato A, Takita T, Furuhashi M, et al. Comparison of serum albumin, C-reactive protein and carotid atherosclerosis as predictors of 10-year mortality in hemodialysis patients. Hemodil Int. 2010 ; 14 : 226-32.
PubMed
3) Kato A, Takita T, Furuhashi M, et al. Influence of the assay for measuring serum albumin on corrected calcium in chronic hemodialysis patients. Ther Apher Dial. 2011 ; 15 : 540-6.
PubMed
4) 日本透析医学会統計調査委員会. わが国の慢性透析の現況. 2010年12月31日現在.
 
5) Ono M, Aoki Y, Masumoto M, et al. High-dose penicillin G-treatment causes underestimation of serum albumin measured by a modified BCP method. Clin Chim Acta. 2009 ; 407 : 75-6.
PubMed
6) Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008 ; 73 : 391-8.
PubMed
7) K/DOQI, National Kidney Foundation. Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2000 ; 35 (6 suppl 2) : S1-S140.
 
8) Fouque D, Vennegoor M, Wee PT, et al. EBPG guideline on nutrition. Nephrol Dial Transplant. 2007 ; 22 (suppl 2) : ii45-ii87.
 
9) 日本透析医学会統計調査委員会. わが国の慢性透析の現況. 2009年12月31日現在.
 
P.94 掲載の参考文献
1) Miida T, Nishimura K, Okamura T, et al. A multicenter study on the precision and accuracy of homogeneous assays for LDLcholesterol : comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. Atherosclerosis. 2012 ; 225 : 208-15.
 
2) KDIGO clinical practice guidline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013 ; 3 : 259-305.
 
3) Shoji T, Masakane I, Watanabe Y, et al. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol. 2011 ; 6 : 1112-20.
PubMed
4) 日本透析医学会. 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌. 2011 ; 44 : 337-425.
 
P.99 掲載の参考文献
1) 市原清志, 河口勝憲, 編著. エビデンスに基づく検査診断実践マニュアル. 大阪 : 日本教育研究センター社 ; 2011. p.114-6.
 
2) 日本動脈硬化学会. 動脈硬化性疾患予防ガイドライン 2017年度.
 
3) 塚本和久. 脂質異常症の臨床検査. 日本内科学会雑誌. 2013 ; 102 : 3117-24.
 
4) 寺本民生. 脂質代謝異常. In : 矢崎良雄, 総編集. 内科学. 10版. 東京 : 朝倉書店 ; 2013. p.1822-9.
 
5) KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013 ; 3 : 259-305.
 
6) 山下計太. ヘパリン投与患者の中性脂肪測定における遊離グリセロールの挙動. 日本臨床検査自動化学会会誌. 2011 ; 36 : 694.
Medical*Online
7) Ueno T, Doi S, Nakashima A, et al. The serum lipid levels may be underestimated in patients on hemodialysis. Inter Med. 2015 ; 54 : 887-94.
 
8) 嶋英昭, 庄司哲雄. 慢性腎臓病 (CKD) の取り扱い. The Lipid. 2013 ; 24 : 67-74.
Medical*Online
9) 日本腎臓学会. 医師・コメディカルのための慢性腎臓病生活・食事指導マニュアル. 東京 : 東京医学社 ; 2015.
 
10) 庄司哲雄. 慢性腎臓病における脂質異常症管理ガイドライン. 日本腎臓学会誌. 2013 ; 55 : 1267-75.
 
11) 日本透析医学会. 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌. 2011 ; 44 : 337-425.
 
P.103 掲載の参考文献
1) Pearson TA, Mensah GA, Alexander WA, et al. Markers of inflammation and cardiovascular disease : Application to clinical and public health practice : A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 ; 107 : 499-511.
 
2) Ridker PM. High-sensitivity C-reactive protein potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001 ; 103 : 1813-8.
PubMed
3) Kawaguchi T, Tong L, Robinson BM, et al. C-reactive protein and mortality in hemodialysis patients : The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clin Pract. 2011 ; 117 : c167-78.
 
4) Stenvinkel P, Heimburger O, Lindholm B, et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation, and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2000 ; 15 : 953-60.
PubMed
P.110 掲載の参考文献
1) 椿原美治, 西慎一, 秋葉隆, 他. 慢性腎臓病患者における腎性貧血治療のガイドライン. 2008年度版. 日本透析医学会 ; 2008.
 
2) 新津洋司郎, 小船雅義. 鉄欠乏性貧血. In : 浅野茂隆, 他監修. 三輪血液病学. 第3版. 東京 : 文光堂 ; 2006. p.1000-17.
 
3) 山中茂雄, 久原太助, 森本みゆき, 他. 臨床検査項目の個体内日内変動に関する検討. 医学検査. 2004 ; 53 : 853-9.
Medical*Online
4) 水口隆, 岡田和美, 水口潤, 他. 血液透析患者の鉄代謝指標の日内変動. 日本透析医学会雑誌. 2010 ; 43 : 493-9.
 
5) Shedlofsky SI. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question. Am J Gastroenterol. 2002 ; 97 : 1093-6.
PubMed
6) KDOQI, National Kidney Foundation. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006 ; 47 (5 Suppl 3) : S11-145.
 
7) 日本腎臓学会. CKD診療ガイド 2012. 2012年6月1日.
 
8) Kidney Disease : Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012 ; 2 : 279-335.
 
9) 2015年度版日本透析医学会慢性腎臓病における腎性貧血治療のガイドライン. 透析会誌. 2016 ; 49 : 89-158.
 
10) Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulatescellular iron efflux by binding to ferroport in andinducing its internalization. Science. 2004 ; 306 : 2090-3.
 
P.115 掲載の参考文献
1) 日本透析医学会. 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン (Clinical Practice Guideline for CKD-MBD). 日本透析医学会誌. 2012 ; 45 : 301-56.
 
2) Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update : what's changed and why it matters Kidney Int. 2017 ; 92 : 26-36.
PubMed
3) Eidman KE, Wetmore JB. The role of parathyroidectomy in the management of secondary hyperparathyroidism. : Curr Opin Nephrol Hypertens. 2017 ; 26 : 516-22.
PubMed
4) Taniguchi M, Fukagawa M, Fujii N, et al ; Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial. 2013 ; 17 : 221-8.
PubMed
P.119 掲載の参考文献
1) Gejyo F, Homma N, Suzuki Y, et al. Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med. 1986 ; 314 : 585-6.
PubMed
2) Floege J, Bartsch A, Schulze M, et al. Clearance and synthesis rates of beta 2-microglobulin in patients undergoing hemodialysis and in normal subjects. J Lab Clin Med. 1991 ; 118 : 153-65.
PubMed
3) Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients : results of the HEMO study. J Am Soc Nephrol. 2006 ; 17 : 546-55.
PubMed
4) Cheung AK, Greene T, Leypoldt JK, et al. HEMO Study Group : Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2008 ; 3 : 69-77.
 
5) Okuno S, Ishimura E, Kohno K, et al. Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. Nephrol Dial Transplant. 2009 ; 24 : 571-7.
PubMed
6) Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun. 1985 ; 129 : 701-6.
PubMed
7) Cianciolo G, Coli L, La Manna G, et al. Is beta2-microglobulinrelated amyloidosis of hemodialysis patients a multifactorial disease? A new pathogenetic approach. Int J Artif Organs. 2007 ; 30 ; 864-78.
 
8) Yamada T, Sotoh T. Changes in individual serum beta 2-microglobulin in regular hemodialysis. Clin Nephrol. 2003 ; 60 : 63-4.
 
9) Patient Registration Committee JSDT. An overview of chronic dialysis treatment in Japan (as December 1998) Tokyo, Japanese Society for Dialysis Therapy. 1999.
 
10) 日本透析医学会. 維持血液透析ガイドライン : 血液透析処方. 透析会誌. 2013 ; 46 : 587-632.
 
P.130 掲載の参考文献
1) Recommendations for preventing transmission of infections among chronic hemodialysis patients. http://www.cdc.gov/mmwr/PDF/rr/rr5005.pdf
 
2) 日本肝臓学会. B型肝炎治療ガイドライン (第3版) 2017年8月. http://www.jsh.or.jp/medical/guidelines/jsh_guidelines/hepatitis_b
 
3) Charest AH, Grand' Maison A, McDougall J, et al. Evolution of naturally acquired hepatitis B immunity in the long-term hemodialysis population. Am J Kidney Dis. 2003 ; 42 : 1193-9.
 
4) 第5章 各種感染症患者に対する感染予防. I. B型肝炎ウイルス (HBV), C型肝炎ウイルス (HCV). 透析医療における標準的な透析操作と感染予防に関するガイドライン (四訂版). 2015. p.81-9.
 
P.138 掲載の参考文献
1) 日本透析医学会統計調査委員会, 編. わが国の慢性透析療法の現況. 2007年12月31日現在.
 
2) Iwasa Y, Otsubo S, Sugi O, et al. Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol. 2008 ; 12 : 53-7.
PubMed
3) 平成19年度厚生労働科学研究費補助金 肝炎等克服緊急対策研究事業 透析施設におけるC型肝炎院内感染の状況・予後・予防に関する研究. 透析医療における標準的な透析操作と院内感染予防に関するマニュアル (三訂版). 2008.
 
4) Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients ; meta-analysis of observational studies. J Viral Hepatitis. 2007 ; 14 : 697-703.
PubMed
5) 日本透析医学会. 透析患者のC型ウイルス肝炎治療ガイドライン. 透析会誌. 2011 ; 44 : 481-531.
 
6) KDIGO : KDIGO Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney Int. 2008 ; 73 (Suppl 109) : S10-9.
 
7) 日本肝臓学会 : C型肝炎治療ガイドライン. https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c
 
P.145 掲載の参考文献
1) Shinzato T, Nakai S, Fujita Y, et al. Determination of Kt/V and protein catabolic rate using pre-and postdialysis blood urea nitrogen concentrations. Nephron. 1994 ; 67 : 280-90.
 
2) 鈴木一之, 井関邦敏, 中井滋, 他. 血液透析条件・透析量と生命予後-日本透析医学会の統計調査結果から-. 日本透析医学会雑誌. 2010 ; 43 : 551-9.
 
3) Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis : associations with reduced mortality in the DOPPS. Kidney Int. 2006 ; 69 : 1222-8.
PubMed
4) 日本透析医学会. 維持血液透析ガイドライン : 血液透析処方. 日本透析医学会雑誌. 2013 ; 46 : 587-632.
 
5) Lowrie EG. The normalized treatment ratio (Kt/V) is not the best dialysis dose parameter. Blood Purif. 2000 ; 18 : 286-94.
 
6) Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006 ; 48 (Suppl 1) : S2-90.
 
7) Eknoyan, G, Beck GJ, Cheung AK, et al. Hemodialysis (HEMO) Study Group : Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002 ; 347 : 2010-9.
 
8) Chertow GM, Owen WF, Lazarus JM, et al. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int. 1999 ; 56 : 1872-8.
 
9) Port FK, Wolfe RA, Hulbert-Shearon TE, et al. High dialysis dose is associated with lower mortality among women but not among men. Am J Kidney Dis. 2004 ; 43 : 1014-23.
 
10) 山本達生, 新里高弘. nPCRを求めるための簡易式. 日本血液浄化技術学会会誌. 2012 ; 20 : 21-9.
 
11) 日本透析医学会統計調査委員会. わが国の慢性透析療法の現況. 2001年12月31日現在. 2002.
 
12) 慢性腎臓病に対する食事療法基準 2007年版 腎疾患の食事療法ガイドライン改訂委員会報告. 日本腎臓学会誌. 2007 ; 49 : 871-8.
 

[III] 病態に応じて行われる検査

P.149 掲載の参考文献
1) αアミラーゼとアミラーゼアイソザイム. In : 金井正光, 監修. 臨床検査法堤要 (改訂33版). 東京 : 金原出版 ; 2010. p.521-7.
 
2) Tianos EV, Darlanons NA, Elisaf M, et al. The value of α amylase and isoamylase determination in chronic renal failure patient. Int J Pancretol. 1994 ; 15 : 105-11.
 
3) Vaziri ND, Chang D, Malekpour A, et al. Pancretic enzyme in patients with end-stage renal disease maintained hemodialysis. Am J Gastroenterol. 1988 ; 83 : 410-24.
 
4) 急性膵炎診療ガイドライン 2015. 第4版. 東京 : 金原出版 ; 2015. p.58-63.
 
P.154 掲載の参考文献
1) Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation. 2007 ; 116 : 2634-53.
PubMed
2) Tsutamoto T, Kawahara C, Yamaji M, et al. Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure. Eur J Heart Fail. 2009 ; 11 : 653-8.
PubMed
3) Lippi G, Tessitore N, Montagnana M, et al. Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. Arch Pathol Lab Med. 2008 ; 132 : 72.
 
4) Wayand D, Baum H, Schatzle G, et al. Cardiac troponin T and I in end-stage renal failure. Clin Chem. 2000 ; 46 : 1345.
PubMed
5) Singhal PC, Barth RH, Ginsberg NS, et al. Determinants of serum creatine kinase activity in dialysis patients. Am J Nephrol. 1988 ; 9 : 220-4.
PubMed
6) Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined- a consensus document of The Joint European Society of Cadriology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Cardiol. 2000 ; 36 : 959-69.
 
7) Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002 ; 106 : 2941-5.
 
8) Iliou MC, Fumeron C, Benoit MO, et al. Prognostic value of cardiac markers in ESRD : Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. Am J Kidney Dis. 2003 ; 42 : 513-23.
PubMed
9) Michos ED, Wilson LM, Yeh HC, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome : a systematic review and meta-analysis. Ann Intern Med. 2014 ; 161 : 491-501.
PubMed
P.160 掲載の参考文献
1) Goldwasser P, Feldman JG, Emiru M, et al. Effect of dialysis modality on fiblinogen concentration : a meta analysis. Am J Kidney Dis. 2004 ; 44 : 941-9.
PubMed
2) Taylor JE, McLaren M, Henderson IS, et al. Prothrombic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant. 1992 ; 7 : 235-9.
 
3) Tekin IO, Pocan B, Borazan A, et al. Positive correlation of CRP and fibrinogen levels as cardiovascular risk factors in early stage of continuous ambulatory peritoneal dialysis patients. Ren Fail. 2008 ; 30 : 219-25.
PubMed
4) DIC診断基準作成委員会. 日本血栓止血学会DIC診断基準暫定案. 日本血栓止血学会誌. 2014 ; 25 : 629-46.
 
5) 山本一郎, 神山剛論, 当麻美樹, 他. 持続血液浄化中に生じる回路内凝固について-多施設アンケート調査より-. ICUとCCU. 2008 ; 32 : S80-3.
 
P.165 掲載の参考文献
1) Luchner A, Hengstenberg C, Lowel H, et al. Effect of compensated renal dysfunction on approved heart failure markers : direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension. 2005 ; 46 : 118-23.
 
2) 石井恵理子, 安藤康宏, 山本尚史, 他. 血液透析 (HD) 患者の血中心房性ナトリウム利尿ペプチド (ANP) 値によるドライウエイト (DW) の判断基準による検討. 透析会誌. 2004 ; 37 : 1417-22.
 
3) Wang AY. Clinical utility of natriuretic peptides in dialysis patients. Semin Dial. 2012 ; 25 : 326-33.
PubMed
4) 日本透析医学会. 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌. 2011 ; 44 : 337-425.
 
5) Wang AY, Lam CW, Wang M, et al. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrol Dial Transplant. 2009 ; 24 : 1962-9.
PubMed
6) 佐野彬子, 山上慎二, 小濱美香, 他. NT-pro BNPとBNPの比較検討-腎機能低下のもたらす影響について-. 医学と薬学. 2012 ; 67 : 121-6.
 
P.169 掲載の参考文献
1) 佐藤弘恵, 風間順一郎, 下条文武. Cystatin C精密測定. モダンメディア. 2006 ; 52 : 17-22.
 
2) 日本腎臓学会. 腎機能の評価法 : 成人. CKD診療ガイド 2012. 東京医学社 ; 2012. p.18-21.
 
3) 槇野久士. IV 臓器障害・合併症評価の検査, 特殊検査, バイオマーカー, シスタチンC. 日本臨牀. 2014 ; 増刊号 6 ; 213-7.
 
4) Shafi T, Michels WM, Levey AS, et al. Estimating residual kidney function in dialysis patients without urine collection. Kidney Int. 2016 ; 89 : 1099-110.
PubMed
5) Inker LA, Perrone RD. Assessment of kidney function. Post TW, ed. UpToDate. Waltham, MA : UpToDate Inc. http://www.uptodate.com (Accsessed on November 26, 2017)
 
P.173 掲載の参考文献
1) Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 ; 23 : 1258-70.
PubMed
2) Sugiyama S, Miyata T, Ueda Y, et al. Plasma levels of pentosidine in diabetic patients : an advanced glycation end product. J Am Soc Nephrol. 1998 ; 9 : 1681-8.
PubMed
3) Rodriguez-Garcia J, Requena JR, Rodriguez-Segade S. Increased concentrations of serum pentosidine in rheumatoid arthritis. Clin Chem. 1998 ; 44 : 250-5.
PubMed
4) Miyata T, Ishiguro N, Yasuda Y, et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun. 1998 ; 244 : 45-9.
PubMed
5) Nakano M, Kubota M, Owada S, et al. The pentosidine concentration in human blood specimens is affected by heating. Amino Acids. 2013 ; 44 : 1451-6.
PubMed
6) 清水孝雄, 監訳. ハーパー・生化学. 東京 : 丸善出版 ; 2016. p.659.
 
7) Machowska A, Sun J, Qureshi AR, et al. Plasma pentosidine and its association with mortality in patients with chronic kidney disease. PLoS One. 2016 ; 11 : e0163826.
PubMed
8) Kitauchi T, Yoshida K, Yoneda T, et al. Association between pentosidine and arteriosclerosis in patients receiving hemodialysis. Clin Exp Nephrol. 2004 ; 8 : 48-53.
PubMed
9) Kakuta T, Tanaka R, Hyodo T, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis. 2011 ; 57 : 422-31.
PubMed
10) Kerkeni M, Weiss IS, Jaisson S, et al. Increased serum concentrations of pentosidine are related to presence and severity of coronary artery disease. Thromb Res. 2014 ; 134 : 633-8.
PubMed
11) Kerkeni M, Saidi A, Bouzidi H, et al. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res. 2013 ; 10 : 239-45.
PubMed
12) Okazaki K, Yamaguchi T, Tanaka K, et al. Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis. Calcif Tissue Int. 2012 ; 91 : 286-96.
PubMed
13) Mitome J, Yamamoto H, Saito M, et al. Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients. Calcif Tissue Int. 2011 ; 88 : 521-9.
PubMed
14) Iwasaki Y, Kazama JJ, Yamato H, et al. Altered material properties are responsible for bone fragility in rats with chronic kidney injury. Bone. 2015 ; 81 : 247-54.
PubMed
15) 斎藤充, 丸毛啓史. 骨質の評価. Bone Joint Nerve. 2016 ; 6 : 43-53.
Medical*Online
P.178 掲載の参考文献
1) Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev. 1996 ; 17 : 45-63.
PubMed
2) Zoccali C, Mallamaci F, Tripepi G, et al. Low triiodothyronine and survival in end-stage renal disease. Kidney Int. 2006 ; 70 : 523-8.
PubMed
3) Enia G, Panuccio V, Cutrupi S, et al. Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2007 ; 22 : 538-44.
PubMed
4) 竹田慎一, 道岸隆敏, 家城恭彦, 他. 接続チューブ保護キャップのポピドンヨードにより甲状腺機能低下を呈した夜間腹膜透析患者の1例. 透析会誌. 1996 ; 29 : 1555-60.
 
5) Sato K, Ohmori T, Shiratori K, et al. Povidone iodine-induced overt hypothyroidism in a patient with prolonged habitual gargling : urinary excretion of iodine after gargling in normal subjects. Intern Med. 2007 ; 46 : 391-5.
 
P.181 掲載の参考文献
1) Morse SA, Dang A, Thakur V, et al. Hypertension in chronic dialysis patients : pathophysiology, monitoring, and treatment. Am J Med Sci. 2003 ; 325 : 194-201.
PubMed
2) Epstein M, Sancho J, Perez G, et al. Volume as a determinant of plasma aldosterone in anephric man. J Clin Endocrinol Metab. 1978 ; 46 : 309-16.
 
3) Gordon RD, Wolfe LK, Island DP, et al. A diurnal rhythm in plasma renin activity in man. J Clin Invest. 1966 ; 45 : 1587-92.
 
4) Kimura G, Takahashi N, Kawano Y, et al. Plasma renin activity in hemodialyzed patients during long-term follow-up. Am J Kidney Dis. 1995 ; 25 : 589-92.
PubMed
5) Tetsuo H, Seto S, Yamazaki H, et al. A serine protease inhibitor, nafamostat mesilate, suppresses aldosterone secretions in vivo. Hypertens Res. 2004 ; 27 : 979-84.
PubMed
P.187 掲載の参考文献
1) Vigna L, Buccianti G, Orsatti A, et al. The impact of long-term hemodialysis on pituitary-adrenocortical function. Ren Fail. 1995 ; 17 : 629-37.
PubMed
2) Letizia C, Mazzaferro S, De Ciocchis A, et al. Effects of haemodialysis session on plasma beta-endorphin, ACTH and cortisol in patients with end-stage renal disease. Scand J Urol Nephrol. 1996 ; 30 : 399-402.
PubMed
3) Wallace EZ, Rosman P, Toshav N, et al. Pituitary-adrenocortical function in chronic renal failure : studies of episodic secretion of cortisol and dexamethasone suppressibility. J Clin Endocrinol Metab. 1980 ; 50 : 46-51.
PubMed
4) Siamopoulos KC, Dardamanis M, Kyriaki D, et al. Pituitary adrenal responsiveness to corticotropin-releasing hormone in chronic uremic patients. Perit Dial Int. 1990 ; 10 : 153-6.
PubMed
5) Clodi M, Riedl M, Schmaldienst S, et al. Adrenal function in patients with chronic renal failure. Am J Kidney Dis. 1998 ; 32 : 52-5.
PubMed
6) 柳瀬敏彦, 笠山宗正, 岩崎泰正, 他. 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日本内分泌会誌. 2015 ; 91 (Suppl.) : 1-78.
 
7) Sakao Y, Sugiura T, Tsuji T, et al. Clinical manifestation of hypercalcemia caused by adrenal insufficiency in hemodialysis patients : a case-series study. Intern Med. 2014 ; 53 : 1485-90.
PubMed
8) Luger A, Lang I, Kovarik J, et al. Abnormalities in the hypothalamic-pituitary-adreno-cortical axis in patients with chronic renal failure. Am J Kidney Dis. 1987 ; 9 : 51-4.
 
9) Grant AC, Rodger RSC, Mitchell R, et al. Hypothalamo-pituitaryadrenal axis in uraemia : evidence for primary adrenal dysfunction? Nephrol Dial Transplant. 1993 ; 8 : 307-10.
 
10) Ramirez G, Bittle PA, Sanders H, et al. The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin. J Clin Endocrinol Metab. 1994 ; 78 : 63-9.
PubMed
11) Ramirez G, Gomez-Sanchez C, Meikle WA, et al. Evaluation of the hypothalamic hypophyseal adrenal axis in patients receiving long-term hemodialysis. Arch Intern Med. 1982 ; 142 : 1448-52.
PubMed
12) Van Herle AJ, Birnbaum JA, Slomowitz LA, et al. Paper chromatography prior to cortisol RIA allows for accurate use of the dexamethasone suppression test in chronic renal failure. Nephron. 1998 ; 80 : 79-84.
PubMed
13) Mise K, Ubara Y, Sumida K, et al. Cushing's syndrome after hemodialysis for 21 years. J Clin Endocrinol Metab. 2013 ; 98 : 13-9.
PubMed
14) Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003 ; 348 : 727-34.
PubMed
15) Hamrahian AH, Oseni TS, Arafah BM. Measurement of serum free cortisol in critically ill patients. N Engl J Med. 2004 ; 350 : 1629-38.
PubMed
P.194 掲載の参考文献
1) 日本内分泌学会, 日本骨代謝学会, 厚生労働省難治性疾患克服研究事業ホルモン受容体機構異常に関する調査研究班. ビタミンD不足・欠乏の判定指針. 日本内分泌学会雑誌. 2017 ; 93 : 1-10.
 
2) 津川尚子. ビタミンD代謝物の測定. The Bone. 2016 ; 40 : 335-42.
 
3) 渭原博, ビタミンD測定の進歩. 臨床検査. 2011 ; 55 : 967-72.
 
4) 三浦雅一. ビタミンDの分析. In : 岡野登志夫, 編. 改訂版ビタミンDと疾患 基礎の理解と臨床への応用. 大阪 : 医薬ジャーナル社 ; 2014. p.33-9.
 
5) Tebben PT, Kumar R. The hormonal regulation of calcium metabolism. In : Alpern RJ, et al. editors. Seldin and Giebisch's The Kidney. 5th ed. Elsevier ; 2013. p.2247-72.
 
6) Nakao C, Hamano T, Fujii N, et al. Combined use of vitamin D status and FGF-23 for risk stratification of renal outcome. Clin Am SocNephrol. 2012 ; 7 : 810-9.
 
7) Rojas-Rivera J, De La Piedra C, Ramos A, et al. The expanding spectrum of biological action of vitamin D. Nephrol Dial Transplant. 2010 ; 25 : 2850-65.
PubMed
8) Autier P, Gandini S. Vitamin D supplementation and total mortality : a meta-analysis of randomized controlled trial. Arch Intern Med. 2007 ; 167 : 1730-7.
PubMed
9) Duranton F, Rodriguez-Ortiz ME, Duny Y, et al. Vitamin D treatment and mortality in chronic kidney disease : A systemic review and meta-analysis. Am J Nephrol. 2013 ; 37 : 239-48.
 
10) 日本透析医学会. 慢性腎臓病に伴う骨ミネラル代謝異常の診療ガイドライン. 透析会誌. 2012 ; 45 : 300-56.
 
11) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Work Group : KDIGO clinical practiceguideline for the diagnosis, evaluation, preventionand treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009 ; 76 (Suppl 113) : S1-S130.
 
P.200 掲載の参考文献
1) Schmidt M, Burchardi C, Sitter T, et al. Procalcitonin in patients undergoing chronic hemodialysis. Nephron. 2000 ; 84 : 187-8.
PubMed
2) Nagata T, Yasuda Y, Ando M, et al. Clinical impact of kidney function on presepsis levels. PLos One. 2015 ; 10 : e0129159.
 
3) 今川朱美, 魚住恵里子, 潮田友紀, 他. プレセプシン値に及ぼす腎機能障害の影響. 医学検査. 2015 ; 64 : 169-72.
Medical*Online
4) 金子守, 岡村佳和. 新規敗血症マーカーとしての「プレセプシン」. 生物試料分析. 2014 ; 37 : 311-20.
Medical*Online
5) Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign : International guidelines for management of sepsis and septic shock : 2016. Crit Care Med. 2017 ; 45 : 486-552.
PubMed
6) 西田修, 小倉裕司, 井上茂亮, 他. 日本版敗血症診療ガイドライン 2016. The Japanese clinical practice guidelines for management of sepsis and septic shock 2016 (J-SSCG 2016). 日救急医会誌. 2017 ; 28 : S1-S232.
 
7) Endo S, Suzuki Y, Takahashi G, et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis : a multicenter prospective study. J Infect Chemother. 2014 ; 20 : 30-4.
PubMed
8) Masson S, Caironi P, Spanuth E, et al. Presepsin (solble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis : data from the Albumin Italian Outcome Sepsis trial. Crit Care. 2014 ; 18 : R6.
 
9) Sitter T, Schmidt M, Schneider S, et al. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol. 2002 ; 15 : 297-301.
PubMed
10) Herget-Rosenthal S, Marggraf G, Pietruck F, et al. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant. 2001 ; 16 : 975-9.
PubMed
11) Shiota J, Ohura N, Higashikawa S, et al. Presepsin as a predictor of critical colonization in CLI hemodialysis patients. Wound Repair Regen. 2016 ; 24 : 189-94.
PubMed
12) Meisner M, Huttemann E, Lohs T, et al. Elimination of procalcitonin and plasma concentrations during continuous veno-venous haemodiafiltration in septic patients. Eur J Anaesthesiol. 2000 ; 17 : 665-71.
PubMed
P.204 掲載の参考文献
1) Pai M, Zwerling A, Menzie D. Systematic review : T-cell-based assays for the diagnosis of latent tuberculosis infection : An update. Ann Intern Med. 2008 ; 149 : 177-84.
 
2) Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-γ release assays for detecting active TB. Chest. 2010 ; 137 : 952-68.
 
3) 厚生労働省科学研究. 感染症法に基づく結核の接触者健康診断の手引き. 改訂第5版. 2014.
 
4) Higuchi K, Sekiya Y, Igari H, et al. Comparison of specificities between two interferon-gamma release assays in Japan. Int J Tuberc Lung Dis. 2012 ; 16 : 1190-2.
PubMed
5) Lee SW, Oh DK, Lee SH, et al. Time interval to conversion of interferon-γ release assay after exposure to tuberculosis. Eur Respir J. 2011 ; 37 : 1447-52.
 
6) American Thoracic Society, CDC : The tuberculin skin test. Am Rev Respir Dis. 1981 ; 124 : 356-63.
 
7) Komiya K, Ariga H, Nagai H, et al. Impact of peripheral lymphocyte count on the sensitivity of 2 IFN-γ release assays, QFT-G and ELISPOT, in patients with pulmonary tuberculosis. Intern Med. 2010 ; 49 : 1849-55.
 
8) Mandalakas AM, Detjen AK, Hesseling AC, et al. Interferon-gamma release assays and childhood tuberculosis : systematic review and meta-analysis. Int J Tuberc Lung Dis. 2011 ; 15 : 1018-32.
PubMed
9) 日本結核病学会予防委員会. インターフェロンγ遊離試験使用指針. Kekkaku. 2014 ; 89 : 717-25.
Medical*Online
P.208 掲載の参考文献
1) Kitada S, Kobayashi K, Ichiyama S, et al. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respire Crit Care Med. 2008 ; 177 : 793-7.
 
2) 坂谷光則. 第73回総会教育講演, 非結核性抗酸菌症の疫学と臨床. 結核. 1999 ; 74 : 377-84.
 
3) Watanabe M, Banno S, Sasaki K, et al. Serodiagnosis of Mycobacterium avium-complex pulmonary disease with an enzyme immunoassay kit that detects anti-glycopeptidolipid core antigen IgA antibodies in patients with rheumatoid arthritis. Mod Rheumatol. 2011 ; 21 : 144-9.
PubMed
4) 北田清悟, 前倉亮治. 第86回総会シンポジウム, MAC症の研究・臨床の最前線 MAC症診断における血清診断法 (妥当性と臨床データ). 結核. 2012 ; 87 : 439-41.
 
5) 日本結核病学会非結核性抗酸菌症対策委員会, 日本呼吸器学会感染症・結核学術部会. 非結核性抗酸菌症診断に関する指針 : 2008年. 結核. 2008 ; 83 : 525-6.
 
P.213 掲載の参考文献
1) 増本英夫, 河野茂, 須山尚史, 他. 剖検例における日和見真菌症の臨床病理学的検討. 日胸疾会誌. 1992 ; 30 : 393-401.
 
2) Obayashi T, Yoshida S, Mori T, et al. Plasma (1→3) βD glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet. 1995 ; 345 : 17-20.
 
3) 丸藤哲, 手戸一郎. 血液透析が深在性真菌症の血清診断におよぼす影響-β-D-グルカンとD-アラビニトール-. 透析会誌. 1991 ; 24 : 1303-5.
 
4) 丸藤哲, 桑原広昌, 住谷俊治, 他. 深在性真菌症と血清診断における問題点-β-D-グルカンとD-アラビニトール-. ICUとCCU. 1991 ; 15 : 279-84.
 
5) 中井滋, 政金生人, 重松隆, 他. わが国の慢性透析療法の現況 (2007年12月31日現在). 日本透析医学会雑誌. 2009 ; 42 : 1-45.
 
6) Kato A, Takita T, Furuhashi M, et al. Elevation of blood (1→3) -beta-D-glucan concentrations in hemodialysis patients. Nephron. 2001 ; 89 : 15-9.
 
7) De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008 ; 46 : 1813-21.
 
P.224 掲載の参考文献
1) Holley JL. Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol. 2007 ; 2 : 604-10.
PubMed
2) 土谷良樹, 乳原善文. 透析患者の合併症マネージメント. 悪性腫瘍. Mebio. 2010 ; 27 : 126-33.
 
3) 大平整爾, 阿部憲司, 長山誠, 他. 慢性血液透析患者における各種腫瘍マーカー測定値の検討. 透析会誌. 1991 ; 24 : 475-83.
 
4) 秋澤忠男, 監修. 深川雅史, 編集. 透析患者の検査値の読み方. 改訂第3版. 東京 : 日本メディカルセンター ; 2013. p.370-91.
 
5) Cases A, Filella X, Molina R, et al. Tumor markers in chronic renal failure and hemodialysis patients. Nephron. 1991 ; 57 : 183-6.
PubMed
6) Arican A, Ozdemir N, Sezer S, et al. Tumor markers in hemodialysis patients. Transplant Proc. 1999 ; 31 : 3367-8.
PubMed
7) 日本臨床検査医学会ガイドライン作成委員会. 臨床検査のガイドラインJSLM2012. 東京 : 日本臨床検査医学会 ; 2012. p.58-62.
 
8) Bellizzi V, de Nicola L, Ames P, et al. Fetal proteins and chronic treatment with low-dose erythropoietin. J Lab Clin Med. 1997 ; 129 : 193-9.
PubMed
9) 生水真紀夫. 検査値を読む 2013 腫瘍マーカー検査 絨毛癌 ヒト絨毛性ゴナドトロピンβサブユニット. 内科. 2013 ; 111 : 1604-5.
 
P.230 掲載の参考文献
1) Okano K, Yumura W, Nitta K, et al. Analysis of lupus activity in end-stage renal disease treated by hemodialysis. Intern Med. 2001 ; 40 : 598-602.
PubMed
2) Gonzalez-Pulido C, Croca S, Abrol E, et al. Long-term activity index after renal failure in a cohort of 32 patients with lupus nephritis. Clin Exp Rheumatol. 2014 ; 32 : 301-7.
 
3) Lionaki S, Hogan SL, Jennette CE, et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 2009 ; 76 : 644-51.
PubMed
P.237 掲載の参考文献
1) プレアルブミン, レチノール結合蛋白, トランスフェリン. SRL医療従事者向け情報 : 検査項目レファレンス/総合検査案内. SRLホームページ.
 
2) 大浜修. アウトカム評価. In : 東口高志, 編. JJNスペシャル「治る」力を引き出す 実践! 臨床栄養. 東京 : 医学書院 ; 2010. p.120-5.
 
3) Aparicio M, Cano N, Chauveau P, et al. Nutritional status of haemodialysis patients : a French national cooperative study. French Study Group for Nutrition in Dialysis. Nephrol Dial Transplant. 1999 ; 14 : 1679-86.
 
4) Fouque D, Kalanta-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein energy wasting in acute and chronic kidney disease. Kidney Int. 2008 ; 73 : 391-8.
 
5) Heng AE, Cano NJM. Nutritional management in adult patients with stage 5 chronic kidney disease on dialysis (both haemodialysis and peritoneal dialysis). NDT Plus. 2010 ; 3 : 109-17.
 
6) Fouque D, Vennegoor M, ter Wee P, et al. EBPG guideline on nutrition. Nephrol Dial Transplant. 2007 ; 22 (suppl 2) : ii45-87.
 
7) Dombros N, Dratwa M, Feriani M, et al. European best practice guidelines for peritoneal dialysis. Nephrol Dial Transplant. 2005 ; 20 (suppl 9) : ix28-33.
 
8) 三木誓雄, 濱田康弘. Topics 15 腎疾患における栄養サポート. 特集 : ESPEN-LLLに学ぶ (後編). 静脈経腸栄養. 2013 ; 28 : 739-64.
 
9) 米川修, 北西朱美, 梶間弘美. 栄養状態の評価. In : 磯崎泰介. 編. 臨床医のための栄養療法の進め方ノート. 東京 : 羊土社 ; 2011. p.43-5.
 
10) Yang JM, Lewandrowski KB. Trace elements, vitamins, and nutrition. Clinical laboratory medicine. Lippincott Williams & Wilkins ; 2002. p.439-62.
 
P.241 掲載の参考文献
1) 宮田學. 諸疾患における亜鉛測定意義-内科領域を中心として-. 亜鉛栄養治療. 2010 ; 1 : 5-25.
 
2) Prasad AS, Beck FW, Bao B, et al. Zinc supplementation decreases incidence of infections in the elderly : effect of zinc on generation of cytokines and oxidative stress. Am J Clin Nutr. 2007 ; 85 : 837-44.
PubMed
3) 塩田潤, 泉治紀, 笠原仁, 他. 血液透析患者において亜鉛 (Zn) は破骨細胞活性を抑制する. 腎と骨代謝. 2012 ; 25 : 161-6.
 
4) Ashton K, Hooper L, Harvey LJ, et al. Methods of assessment of selenium status in humans : a systematic review. Am J Clin Nutr. 2009 ; 89 : 2025S-39S.
PubMed
5) Guo CH, Wang CL, Chen PC, et al. Linkage of some trace elements, peripheral blood lymphocytes, inflammation, and oxidative stress in patients undergoing either hemodialysis or peritoneal dialysis. Perit Dial Int. 2011 ; 31 : 583-91.
PubMed
6) Dworkin B, Weseley S, Rosenthal WS, et al. Diminished blood selenium levels in renal failure patients on dialysis : correlations with nutritional status. Am J Med Sci. 1987 ; 293 : 6-12.
PubMed
7) Salehi M, Sohrabi Z, Ekramzadeh M, et al. Selenium supplementation improves the nutritional status of hemodialysis patients : a randomized, double-blind, placebo-controlled trial. Nephrol Dial Transplant. 2013 ; 28 : 716-23.
PubMed
8) 西牟田守. ミネラル, 微量元素の欠乏と過剰. 臨床栄養. 1996 ; 89 : 485-92.
Medical*Online
P.248 掲載の参考文献
1) Lahjouji K, Mitchell GA, Qureshi IA. Carnitine transport by organic cation transporters and systemic carnitine deficiency. Mol Genet Metab. 2001 ; 73 : 287-97.
PubMed
2) Pons R, De Vivo DC. Primary and secondary carnitine deficiency sundrome. J Child Neurol. 1995 ; 10 (suppl) : 2S8-2S24.
 
3) Bohmer T, Bergrem H, Eiklid K. Carnitine deficiency induced during intermittent haemodialysis for renal failure. Lancet. 1978 ; 1 : 126-8.
PubMed
4) 樋口輝美, 石川由美子, 山崎俊男, 他. 血液透析患者の腎性貧血に対するレボカルニチンの有効性. 透析会誌. 2014 ; 47 : 119-27.
 
5) 樋口輝美, 堀田直, 黒岩奈美, 他. 血液透析患者の心機能に対するレボカルニチンの効果. 透析会誌. 2014 ; 47 : 305-12.
 
6) Higuchi T, Abe M, Yamazaki T, et al. Effects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients : A randomized controlled trial. Nutrients. 2014 ; 6 : 5992-6004.
PubMed
7) Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation in maintenance hemodialysis patients. Am J Kidney Dis. 2003 ; 42 : 761-73.
PubMed
8) Hurot JM, Cucherat M, Haugh M, et al. Effects of L-carnitine supplementation in maintenance hemodialysis patients : A systematic review. J Am Soc Nephrol. 2002 ; 13 : 708-14.
PubMed
9) Maruyama T, Higuchi T, Yamazaki T, et al. Levocarnitine injections decrease the need for erythropoiesis-stimulating agents in hemodialysis patients with renal anemia. Cardiorenal Med. 2017 ; 7 : 179-87.
 
10) van Es A, Henny FC, Kooistra MP, et al. Amelioration of cardiac function by L-carnitine administration in patients on haemodialysis. Contrib Nephrol. 1992 ; 98 : 28-35.
PubMed
11) Sakurabayashi T, Miyazaki S, Yuasa S, et al. L-carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis. Cir J. 2008 ; 72 : 926-31.
 
12) Higuchi T, Abe M, Yamazaki T, et al. Levocarnitine improves cardiac function in hemodialysis patinets with left ventricular hypertrophy : A randomized controlled trial. Am J Kidney Dis. 2016 ; 67 : 260-70.
 
13) Ahmad S, Robertson HT, Golper TA, et al. Multicenter trial of L-carnitine inmaintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int. 1990 ; 38 : 912-8.
PubMed
14) Casciani CU, Caruso U, Cravotto E, et al. Beneficial effects of L-carnitine in post-dialysis syndrome. Curr Ther Res. 1982 ; 32 : 116-27.
 
15) Bellinghieri G, Savica V, Mallamace A, et al. Correlation between increased serum and tissue L-carnitine levels and improved musclesymptoms in hemodialyzed patients. Am J Clin Nutr. 1983 ; 38 : 523-34.
PubMed
16) Sakurauchi Y, Matsumoto Y, Shinzato T, et al. Effects of L-carnitinesupplementation on muscular symptoms in hemodialyzed patients. Am J Kidney Dis. 1998 ; 32 : 258-64.
PubMed
17) Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013 ; 19 : 576-87.
 
18) Tanaka M, Ishii H, Aoyama T, et al. Ankle brachial pressure index but not brachial-ankle pulse wave velocity is a strong predictor of systemic atherosclerotic morbidity and mortality in patients on maintenance hemodialysis. Atherosclerosis. 2011 ; 219 : 643-7.
 
19) Tabibi H, Hakeshzadedh F, Hedayati M, et al. Effects of L-carnitine supplement on serum amyloid A and vascular inflammation markers in hemodialysis patients : A randomized controlled trial. J Ren Nut. 2011 ; 21 : 485-91.
 
20) Duranay M, Akay H, Yilmaz FM, et al. Effects of L-carnitine infusions on inflammatory and nutritional markers in hemodialysis patients. Nephrol Dial Transplant. 2006 ; 21 : 3211-4.
PubMed
21) Vesela E, Racek J, Trefil L, et al. Effect of L-carnitine supplementation in hemodialysis patients. Nephron. 2001 ; 88 : 218-23.
PubMed
22) Kudoh Y, Aoyama S, Torii S, et al. Hemodynamic stabilizing effects of L-carnitine in chronic hemodialysis patients. Cardiorenal Med. 2013 ; 3 : 200-7.
 
P.255 掲載の参考文献
1) Yanagisawa N, Shimada K, Miyazaki T, et al. Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area. J Atheroscler Thromb. 2010 ; 17 : 285-94.
 
2) Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease : effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011 ; 58 : 2047-67.
PubMed
3) Shoji T, Kakiya R, Hayashi T, et al. Serum n-3 and n-6 polyunsaturated fatty acid profile as an independent predictor of cardiovascular events in hemodialysis patients. Am J Kidney Dis. 2013 ; 62 : 568-76.
 
4) Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet. 2007 ; 369 : 1090-8.
PubMed
5) Svensson M, Schmidt EB, Jorgensen KA, et al. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis : a randomized, placebocontrolled intervention trial. Clin J Am Soc Nephrol. 2006 ; 1 : 780-6.
PubMed
6) Kuwamura Y, Shoji T, Okute Y, et al. Altered serum n-6 polyunsaturated fatty acid profile and risks of mortality and cardiovascular events in a cohort of hemodialysis patients. J Ren Nutr. 2018 ; 28 : 54-63.
 
P.259 掲載の参考文献
1) 日本TDM学会ホームページ. http://plaza.umin.ac.jp/~jstdm/yogo/kiso/08_tokuteitdm.html
 
2) 唯野貢司, 菅原満, 小林道也, 他. TDM実践ハンドブック. 初版. 東京 : 薬事日報社 ; 2007.
 
3) 日本化学療法学会/日本TDM 学会抗菌薬TDMガイドライン作成委員会, 編. 抗菌薬TDMガイドライン改訂版 2016. 第2版. 東京 : 杏林舎 ; 2016.
 
4) 循環器薬の薬物血中濃度モニタリングに関するガイドライン : 日本循環器学会/日本TDM学会合同ガイドライン. http://jstdm.umin.jp/guidelines/JCS2015_Original.pdf
 
5) Atcheson BA, Taylor PJ, Kirkpatrick CM, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit. 2004 ; 26 : 284-6.
PubMed
6) 日本TDM学会/日本移植学会, 編. 免疫抑制薬TDM標準化ガイドライン <2014> -臓器移植編. 東京 : 金原出版 ; 2014.
 

書評

最近チェックした商品履歴

Loading...